E-ISSN 2277-338X | ISSN 2320-4664
Required files to uploaded
Scale-up of tuberculosis laboratory services in Gujarat, India
Nilesh D Patel.
M. tuberculosis has been classified as risk group 3 pathogen and has to be handled at appropriate containment level. The IRL, Ahmedabad got WHO accreditation in March 08 for Lowenstein-Jensen solid culture and first line anti-tuberculosis drug sensitivity. Immediately after WHO endorsement of line probe assay (LPA) for rapid MDR-TB testing in 2008, Gujarat state leaped forwarded and started research on “Genotype MTB DR Plus assay” in collaboration with WHO. In 2009 this effort gained momentum when the IRL, Ahmedabad was radically upgraded to BSL 3 facility. BSL 3 facility like this can balance risk of air-borne infection. As a minimum, countries embarking on drug-resistant tuberculosis programmes should establish laboratory capacity to diagnose MDR-TB and monitor culture conversion of patients on Category IV treatment. Gujarat has set the example of a truly dynamic tuberculosis management, demonstrating that rapid scale-up of laboratory services for MDR-TB diagnosis is feasible even at regional level, in resource-constrained settings.
RNTCP, Scale-up, Bio-Safety Level
|1. Ramachandran R, Nalini S, Chandrasekar V, Dave PV, Sanghvi AS, Wares F, et al. Surveillance of drug-resistant tuberculosis in the state of Gujarat, India. Int J Tuberc Lung Dis 2009; 13: 1154â€“1160.|
|2. Raizada N, Dewan PK, Malhotra B, KishorReddy VC, Dave P, Sharma P, et al. Establishing laboratory proficiency to conduct the line probe assay for MDR-TB diagnosis. Abstracts of the 40th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease, 2009; Mexico; S304; Abstract No. PC-94473-07.|
|3. Gumusboga AG. Occupational transmission of TB in laboratories. Abstracts of the 38th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease, 2007; Cape Town, South Africa; S33.|